Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

NCT: NCT07218315 · RECRUITING

NCT IDNCT07218315
StatusRECRUITING
Start Date2026-02-11
Completion2031-01-31

Brief Summary

This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T

Frequently Asked Questions

What is Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma?

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma is a clinical trial registered under NCT07218315. Current status: RECRUITING.

What is the status of NCT07218315?

The current status of NCT07218315 (Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma) is: RECRUITING.

When did Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma start?

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma started on 2026-02-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑